NASDAQ:RLMD

Relmada Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024

Retrieved on: 
Monday, May 6, 2024
CNS, Central nervous system, Therapy, Conference

CORAL GABLES, Fla., May 6, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the first quarter ended March  31, 2024 after the market close on Wednesday, May 8, 2024.

Key Points: 
  • CORAL GABLES, Fla., May 6, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the first quarter ended March  31, 2024 after the market close on Wednesday, May 8, 2024.
  • The company will host a corporate update conference call and live audio webcast at 4:30 p.m. Eastern Time on Wednesday, May 8, 2024.
  • Live Conference Call & Webcast:

Relmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024

Retrieved on: 
Tuesday, March 12, 2024
Central nervous system, CNS, Conference, Therapy

CORAL GABLES, Fla., March 12, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2023 after the market close on Tuesday, March 19, 2024.

Key Points: 
  • CORAL GABLES, Fla., March 12, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2023 after the market close on Tuesday, March 19, 2024.
  • The company will host a corporate update conference call and live audio webcast at 4:30 p.m. Eastern Time on Tuesday, March 19, 2024.
  • Live Conference Call & Webcast:

Relmada Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

Retrieved on: 
Tuesday, March 5, 2024
Central nervous system, SVB Securities, Therapy, CNS, Conference

CORAL GABLES, Fla., March 5, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer will participate in the Leerink Partners Global Biopharma Conference in one-on-one investor meetings, taking place March 11-13, 2024, in Miami Beach, Florida.

Key Points: 
  • CORAL GABLES, Fla., March 5, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer will participate in the Leerink Partners Global Biopharma Conference in one-on-one investor meetings, taking place March 11-13, 2024, in Miami Beach, Florida.
  • Please see below for additional details about the event and how to request a one-on-one meeting with management.
  • Conference Date: March 11 – March 13, 2024
    Please contact your Leerink Partners representative if you would like to schedule a one-one-one meeting with Relmada management.

Relmada Therapeutics to Report Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 8, 2023

Retrieved on: 
Friday, November 3, 2023
CORAL, Conference, Therapy, CNS, Central nervous system, Pharmaceutical industry, Broadcasting

CORAL GABLES, Fla., Nov. 3, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the third quarter ended September 30, 2023 after the market close on Wednesday, November 8, 2023.

Key Points: 
  • CORAL GABLES, Fla., Nov. 3, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the third quarter ended September 30, 2023 after the market close on Wednesday, November 8, 2023.
  • The company will host a corporate update conference call and live audio webcast at 4:30 p.m. Eastern Time on Wednesday, November 8, 2023.
  • Live Conference Call & Webcast:

Relmada Therapeutics to Present New Preclinical Data on its Psilocybin Program at AASLD The Liver Meeting® 2023

Retrieved on: 
Wednesday, October 11, 2023
Weight gain, Hepatology, Central nervous system, Mouse, AASLD, Psilocybin, Hyperglycemia, CORAL, American Association for the Study of Liver Diseases, Therapy, Liver, Hyperlipidemia, CNS, Dietary supplement

The data demonstrate the beneficial effect of non-psychedelic/low dose psilocybin on multiple metabolic parameters in a rodent model of metabolic dysfunction-associated steatotic liver disease (MASLD).

Key Points: 
  • The data demonstrate the beneficial effect of non-psychedelic/low dose psilocybin on multiple metabolic parameters in a rodent model of metabolic dysfunction-associated steatotic liver disease (MASLD).
  • Relmada intends to enter human studies of its proprietary, non-psychedelic/low dose modified-release formulation of psilocybin for metabolic indications.
  • "There are currently no approved drugs for MASLD, and these initial pre-clinical results support the therapeutic potential of non-psychedelic/low dose psilocybin.
  • Abstract Number: 2468-C, THE SEROTONIN RECEPTOR AGONIST PSILOCYBIN AS A NOVEL THERAPEUTIC APPROACH FOR NAFLD: PRECLINICAL STUDIES.

Relmada Therapeutics to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit

Retrieved on: 
Monday, October 9, 2023
CORAL, Central nervous system, Therapy, Jefferies, Webcast, CNS

Relmada management will also be available for one-one-one investor meetings during the conference.

Key Points: 
  • Relmada management will also be available for one-one-one investor meetings during the conference.
  • Please contact your Jefferies representative if you would like to schedule a meeting.
  • The webcast can also be accessed via the Investors section of the Relmada website at https://www.relmada.com/for-investors .
  • An archived replay will be available for 90 days following the conclusion of the event.

Relmada Therapeutics to Present Data from its REL-1017 and Psilocybin Programs at the 36th European College of Neuropsychopharmacology (ECNP) Congress

Retrieved on: 
Friday, October 6, 2023
Congress, Central nervous system, C57BL/6J, Therapy, CORAL, European College of Neuropsychopharmacology, Psilocybin, CNS, Data, ECNP, CEST, Pharmaceutical industry

CORAL GABLES, Fla., Oct. 6, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will present three posters at the upcoming 36th European College of Neuropsychopharmacology (ECNP) Congress, taking place October 7-10, 2023, in Barcelona, Spain.

Key Points: 
  • CORAL GABLES, Fla., Oct. 6, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will present three posters at the upcoming 36th European College of Neuropsychopharmacology (ECNP) Congress, taking place October 7-10, 2023, in Barcelona, Spain.
  • Details of the poster presentations are as follows:
    Date & Time of Presentations: Sunday, October 8, 2023, 12:35-2:00pm CEST
    Poster Title: Behavioral effects of a 14-day repeated treatment with psilocybin at a low non-psychedelic dose: a preliminary study in C57BL/6J mice
    The posters will be available in the Data and Publications section of the Relmada website following the conclusion of the event.
  • For additional information about ECNP 2023, click here .

Relmada Therapeutics to Report Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 8, 2023

Retrieved on: 
Tuesday, August 1, 2023
CORAL, Central nervous system, Therapy, Conference, CNS, Rare-earth element, Broadcasting, Pharmaceutical industry

CORAL GABLES, Fla., Aug. 1, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the second quarter ended June 30, 2023 after the market close on Tuesday, August 8, 2023.

Key Points: 
  • CORAL GABLES, Fla., Aug. 1, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the second quarter ended June 30, 2023 after the market close on Tuesday, August 8, 2023.
  • The company will host a corporate update conference call and live audio webcast at 4:30 p.m. Eastern Time on Tuesday, August 8, 2023.
  • Live Conference Call & Webcast:

Bragar Eagel & Squire, P.C. Is Investigating Relmada, Arrival, FMC, and Viasat and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, July 27, 2023
P.C, ARVL, Depression, TD, Market, VSAT, MADRS, Arrival, Acquisition, MDD, FMC Corporation, FMC, News, NYSE, Major depressive disorder, Pharmaceutical industry, Cryptocurrency, Audit, Communications satellite, Viasat

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • Additional information about each case can be found at the link provided.
  • Before market opened on October 13, 2022, Relmada announced the results of its RELIANCE III study (REL-1017-303), evaluating the drug REL-1017 as a monotherapy for Major Depressive Disorder (MDD).
  • Specifically, the REL-1017 treatment showed a MADRS reduction of 14.8 points at Day 28 versus 13.9 points for placebo, a higher-than-expected placebo response.

Bragar Eagel & Squire, P.C. Is Investigating Waldencast, Relmada, DoubleVerify, and Castle and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, July 22, 2023
P.C, Depression, Bank statement, Zein E. Obagi, DV, MADRS, Sale, MDD, American Society of Clinical Oncology, WALD, Annual report, Society, News, NYSE, Major depressive disorder, Cryptocurrency, Audit, Pharmaceutical industry

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • Additional information about each case can be found at the link provided.
  • Specifically, the Company is conducting an analysis regarding certain accounting issues in connection with the sale of certain Obagi products for the Vietnam market.
  • On this news, DoubleVerify’s share price fell $1.69, or 5.8%, to close at $27.22 per share on May 2, 2023, thereby injuring investors.